Synthetic Bacteria for Therapeutics = Synthetic Bacteria for Therapeutics

다국어 초록 (Multilingual Abstract)

Synthetic biology builds programmed biological systems for a wide range of purposes such as improving human health, remedying the environment, and boosting the production of valuable chemical substances. In recent years, the rapid development of synthetic biology has enabled synthetic bacterium-based diagnoses and therapeutics superior to traditional methodologies by engaging bacterial sensing of and response to environmental signals inherent in these complex biological systems. Biosynthetic systems have opened a new avenue of disease diagnosis and treatment. In this review, we introduce designed synthetic bacterial systems acting as living therapeutics in the diagnosis and treatment of several diseases. We also discuss the safety and robustness of genetically modified synthetic bacteria inside the human body.

참고문헌 (Reference)

1 이은숙, "[MINIREVIEW] Probiotics in human health and disease: from nutribiotics to pharmabiotics" 한국미생물학회 56 (56): 773-782, 2018

2 Hamady ZZ, "Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus" 59 : 461-469, 2010

3 Wegmann U, "Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect" 7 : 2294-, 2017

4 Stritzker J, "Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917in live mice" 297 : 151-162, 2007

5 Duchmann R, "Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease(IBD)" 102 : 448-455, 1995

6 Lenz DH, "The small RNA chaperone Hfq and multiple small RNAs control quorum sensing in Vibrio harveyi and Vibrio cholerae" 118 : 69-82, 2004

7 Hensel M, "The genetic basis of tetrathionate respiration in Salmonella typhimurium" 32 : 275-287, 1999

8 Bull MJ, "The domestication of the probiotic bacterium Lactobacillus acidophilus" 4 : 7202-, 2014

9 Gerdes K, "The Parb(Hok Sok)Locus of plasmid-R1-a general-purpose plasmid stabilization system" 6 : 1402-1405, 1988

10 Claesen J, "Synthetic microbes as drug delivery systems" 4 : 358-364, 2015

11 Ruder WC, "Synthetic biology moving into the clinic" 333 : 1248-1252, 2011

12 Mays ZJ, "Synthetic biology in probiotic lactic acid bacteria : at the frontier of living therapeutics" 53 : 224-231, 2018

13 Chakravarti D, "Synthetic biology in cellbased cancer immunotherapy" 33 : 449-461, 2015

14 Abil Z, "Synthetic biology for therapeutic applications" 12 : 322-331, 2015

15 Slomovic S, "Synthetic biology devices for in vitro and in vivo diagnostics" 112 : 14429-14435, 2015

16 Dou J, "Synthetic biology and the gut microbiome" 13 : e1700159-, 2018

17 Ozdemir T, "Synthetic biology and engineered live biotherapeutics : toward increasing system complexity" 7 : 5-16, 2018

18 Folcher M, "Synthetic biology advancing clinical applications" 16 : 345-354, 2012

19 Wang F, "Synthetic biology : Recent progress, biosafety and biosecurity concerns, and possible solutions" 1 : 22-30, 2019

20 Chubukov V, "Synthetic and systems biology for microbial production of commodity chemicals" 2 : 16009-, 2016

21 Din MO, "Synchronized cycles of bacterial lysis for in vivo delivery" 536 : 81-85, 2016

22 Heinzinger NK, "Sequence analysis of the phs operon in Salmonella typhimurium and the contribution of thiosulfate reduction to anaerobic energy metabolism" 177 : 2813-2820, 1995

23 Paddon CJ, "Semi-synthetic artemisinin : a model for the use of synthetic biology in pharmaceutical development" 12 : 355-367, 2014

24 Chen Z, "Recent development on synthetic biological devices treating bladder cancer" 1 : 216-220, 2016

25 Park SH, "RGD Peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated salmonella-mediated cancer therapy" 6 : 1672-1682, 2016

26 Pinero-Lambea C, "Programming controlled adhesion of E, coli to target surfaces, cells, and tumors with synthetic adhesins" 4 : 463-473, 2015

27 Danino T, "Programmable probiotics for detection of cancer in urine" 7 (7): 289ra84-, 2015

28 Kotula JW, "Programmable bacteria detect and record an environmental signal in the mammalian gut" 111 : 4838-4843, 2014

29 Derman AI, "Phylogenetic analysis identifies many uncharacterized actin-like proteins(Alps)in bacteria : regulated polymerization, dynamic instability and treadmilling in Alp7A" 73 : 534-552, 2009

30 Vandenbroucke K, "Orally administered L, lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis" 3 : 49-56, 2010

31 Robert S, "Oral delivery of glutamic acid decarboxylase(GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice" 63 : 2876-2887, 2014

32 Gillum MP, "N-acylphosphatidylethanolamine, a gutderived circulating factor induced by fat ingestion, inhibits food intake" 135 : 813-824, 2008

33 Jain A, "Microbial synthetic biology for human therapeutics" 6 : 9-22, 2012

34 Lee SK, "Metabolic engineering of microorganisms for biofuels production : from bugs to synthetic biology to fuels" 19 : 556-563, 2008

35 Nerup J, "Mechanisms of pancreatic beta-cell destruction in type I diabetes" 11 (11): 16-23, 1988

36 Cook DP, "Lactococcus lactis as a versatile vehicle for tolerogenic immunotherapy" 8 : 1961-, 2017

37 Housley RM, "Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract" 94 : 1764-1777, 1994

38 Panida Sittipo, "Intestinal microbiota and the immune system in metabolic diseases" 한국미생물학회 56 (56): 154-162, 2018

39 Chen Z, "Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity" 124 : 3391-3406, 2014

40 Tisch R, "Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice" 366 : 72-75, 1993

41 Jackson MR, "Human sulfide : quinone oxidoreductase catalyzes the first step in hydrogen sulfide metabolism and produces a sulfane sulfur metabolite" 51 : 6804-6815, 2012

42 Park W, "Gut microbiomes and their metabolites shape human and animal health" 56 : 151-153, 2018

43 Winter SE, "Gut inflammation provides a respiratory electron acceptor for Salmonella" 467 : 426-429, 2010

44 Chen YY, "From DNA to targeted therapeutics : bringing synthetic biology to the clinic" 3 (3): 106-, 2011

45 Liang Q, "Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer" 23 : 2061-2070, 2017

46 Brader P, "Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging" 14 : 2295-2302, 2008

47 Pedrolli DB, "Engineering microbial living therapeutics : the synthetic biology toolbox" 37 : 100-115, 2019

48 Saeidi N, "Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen" 7 : 521-, 2011

49 Daeffler KN, "Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation" 13 : 923-, 2017

50 Riglar DT, "Engineering bacteria for diagnostic and therapeutic applications" 16 : 214-225, 2018

51 Hwang IY, "Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models" 8 : 15028-, 2017

52 Bhattarai SR, "Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection" 33 : 5166-5174, 2012

53 Duan F, "Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model" 107 : 11260-11264, 2010

54 Yamamoto M, "Efficacy of tumor-targeting Salmonella A1-R on a melanoma patient-derived orthotopic xenograft(PDOX)nude mouse model" 11 : e0160882-, 2016

55 Hiroshima Y, "Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patientderived orthotopic xenograft(PDOX)" 115 : 1254-1261, 2014

56 Dosoky NS, "Dietary fatty acids control the species of N-Acylphosphatidylethanolamines synthesized by therapeutically modified bacteria in the intestinal tract" 4 : 3-13, 2018

57 Chassaing B, "Dextran sulfate sodium (DSS)-induced colitis in mice" 104 : Unit 15.25-, 2014

58 Isabella VM, "Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria" 36 : 857-864, 2018

59 김송이, "Current Status of Microbial Phenylethanoid Biosynthesis" 한국미생물·생명공학회 28 (28): 1225-1232, 2018

60 Wright O, "Building-in biosafety for synthetic biology" 159 : 1221-1235, 2013

61 Courbet A, "Bringing next-generation diagnostics to the clinic through synthetic biology" 8 : 987-991, 2016

62 Fangyu Cheng, "Biosynthesis of Chondroitin in Engineered Corynebacterium glutamicum" 한국미생물·생명공학회 29 (29): 392-400, 2019

63 Kramer MG, "Bacterial therapy of cancer : promises, limitations, and insights for future directions" 9 : 16-, 2018

64 Chien T, "Advances in bacterial cancer therapies using synthetic biology" 5 : 1-8, 2017

65 Cameron DE, "A brief history of synthetic biology" 12 : 381-390, 2014